The SARS-CoV-2 variant B.1.1.529 (Omicron) was designated a variant of concern in November 2021
1 and is spreading rapidly. The protection provided by current COVID-19 vaccines is not established. Preliminary studies suggest that antibodies neutralizing Omicron, which carries multiple mutations in the spike protein, critically wane in the months following heterologous infection or vaccination.
2,3 A third vaccine dose seems to boost neutralizing antibodies, although less efficiently than for the B.1.617.2 (Delta) variant.
2 Whether the mutations in Omicron spike protein affect T-cell recognition, which is known to be less affected than antibodies for other variants,
4 is still under investigation.